Brainstorm Cell Therapeutics Inc (BCLI)

Dec 12, 2024

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online

Dec 12, 2024

Dec 12, 2024

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - The Eastern Progress Online

Dec 12, 2024

Dec 11, 2024

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online

Dec 11, 2024

Dec 10, 2024

Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR

Dec 10, 2024

Dec 09, 2024

BrainStorm Cell Therapeutics Announces Major ALS Treatment Webinar with Leading Expert - StockTitan

Dec 09, 2024

Dec 07, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald

Dec 07, 2024

Dec 06, 2024

Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR

Dec 06, 2024

Dec 04, 2024

BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria

Dec 04, 2024

Dec 04, 2024

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard

Dec 04, 2024

Dec 03, 2024

BrainStorm secures patent for exosome technology - Investing.com

Dec 03, 2024

Dec 03, 2024

Brainstorm Cell Therapeutics Inc. Strengthens Exosome Patent Portfolio; Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Marketscreener.com

Dec 03, 2024

Dec 03, 2024

Breakthrough Patent Propels BrainStorm’s Next-Gen Therapies - Smartphone Magazine

Dec 03, 2024

Dec 01, 2024

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Marketscreener.com

Dec 01, 2024

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail

Nov 29, 2024

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR

Nov 29, 2024

Nov 22, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Mini - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024

Nov 18, 2024

Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR

Nov 18, 2024

Nov 15, 2024

Brainstorm Cell Therapeutics Inc. (BCLI) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeu - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Malaysian Reserve

Nov 14, 2024

Nov 14, 2024

BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve

Nov 14, 2024

Nov 11, 2024

Amyotrophic Lateral Sclerosis Market Opportunities, - openPR

Nov 11, 2024

Nov 11, 2024

BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership - StockTitan

Nov 11, 2024

Nov 08, 2024

Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve

Nov 08, 2024

Oct 31, 2024

BCLI stock touches 52-week low at $1.86 amid market challenges - Investing.com

Oct 31, 2024

Oct 30, 2024

BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 30, 2024

BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India

Oct 30, 2024

Oct 29, 2024

Neuromuscular Disease Therapeutics Market Statistical - openPR

Oct 29, 2024

Oct 28, 2024

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PR Newswire

Oct 28, 2024

Oct 27, 2024

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat

Oct 27, 2024

Oct 18, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat

Oct 18, 2024

Oct 17, 2024

Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR

Oct 17, 2024

Oct 16, 2024

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne

Oct 16, 2024

Oct 11, 2024

Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트

Oct 11, 2024

Oct 10, 2024

Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat

Oct 10, 2024

Oct 10, 2024

Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv

Oct 10, 2024

Oct 09, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat

Oct 09, 2024

Oct 07, 2024

BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 07, 2024

Oct 07, 2024

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan

Oct 07, 2024

Oct 04, 2024

Gene and Cell Therapies for CNS Disorders Market to Experience - openPR

Oct 04, 2024